Original Study| Volume 19, ISSUE 4, P328-332.e2, April 2018

Age, Sex, and Dose Effects of Nonbenzodiazepine Hypnotics on Hip Fracture in Nursing Home Residents

Published:November 07, 2017DOI:



      The Food and Drug Administration recommends a reduced dose of nonbenzodiazepine hypnotics in women, yet little is known about the age-, sex-, and dose-specific effects of these drugs on risk of hip fracture, especially among nursing home (NH) residents. We estimated the age-, sex-, and dose-specific effects of nonbenzodiazepine hypnotics on the rate of hip fracture among NH residents.

      Design and Setting

      Case-crossover study in US NHs.


      A total of 691 women and 179 men with hip fracture sampled from all US long-stay NH residents.


      Measures of patient characteristics were obtained from linked Medicare and the Minimum Data Set (2007–2008). The outcome was hospitalization for hip fracture with surgical repair. We estimated rate ratios (RRs) and 95% confidence intervals (CIs) from conditional logistic regression models for nonbenzodiazepine hypnotics (vs nonuse) comparing 0 to 29 days before hip fracture (hazard period) with 60 to 89 and 120 to 149 days before hip fracture (control periods). We stratified analyses by age, sex, and dose.


      The average RR of hip fracture was 1.7 (95% CI 1.5–1.9) for any use. The RR of hip fracture was higher for residents aged ≥90 years vs <70 years (2.2 vs 1.3); however, the CIs overlapped. No differences in the effect of the hypnotic on risk of hip fracture were evident by sex. Point estimates for hip fracture were greater with high-dose versus low-dose hypnotics (RR 1.9 vs 1.6 for any use), but these differences were highly compatible with chance.


      The rate of hip fracture in NH residents due to use of nonbenzodiazepine hypnotics was greater among older patients than among younger patients and, possibly, with higher doses than with lower doses. When clinicians are prescribing a nonbenzodiazepine hypnotic to any NH resident, doses of these drugs should be kept as low as possible, especially among those with advanced age.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the American Medical Directors Association
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • US Food and Drug Administration
        Drug Safety Communication: Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist).
        (Available at:) (Accessed February 3, 2013)
        • Bocca M.L.
        • Marie S.
        • Lelong-Boulouard V.
        • et al.
        Zolpidem and zopiclone impair similarly monotonous driving performance after a single nighttime intake in aged subjects.
        Psychopharmacology. 2011; 214: 699-706
        • Leufkens T.R.
        • Lund J.S.
        • Vermeeren A.
        Highway driving performance and cognitive functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and zolpidem.
        J Sleep Res. 2009; 18: 387-396
        • Verster J.C.
        • Roth T.
        Gender differences in highway driving performance after administration of sleep medication: A review of the literature.
        Traffic Inj Prev. 2012; 13: 286-292
        • Greenblatt D.J.
        • Harmatz J.S.
        • von Moltke L.L.
        • et al.
        Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate.
        Clin Pharmacol Ther. 2004; 76: 467-479
        • Glass J.
        • Lanctot K.L.
        • Herrmann N.
        • et al.
        Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits.
        BMJ. 2005; 331: 1169
        • Fisher E.S.
        • Baron J.A.
        • Malenka D.J.
        • et al.
        Hip fracture incidence and mortality in New England.
        Epidemiology. 1991; 2: 116-122
        • Wang P.S.
        • Bohn R.L.
        • Glynn R.J.
        • et al.
        Zolpidem use and hip fractures in older people.
        J Am Geriatr Soc. 2001; 49: 1685-1690
        • Berry S.D.
        • Lee Y.
        • Cai S.
        • Dore D.D.
        Nonbenzodiazepine sleep medication use and hip fractures in nursing home residents.
        JAMA Intern Med. 2013; 173: 754-761
        • Finkle W.D.
        • Der J.S.
        • Greenland S.
        • et al.
        Risk of fractures requiring hospitalization after an initial prescription for zolpidem, alprazolam, lorazepam, or diazepam in older adults.
        J Am Geriatr Soc. 2011; 59: 1883-1890
        • Kang D.Y.
        • Park S.
        • Rhee C.W.
        • et al.
        Zolpidem use and risk of fracture in elderly insomnia patients.
        J Prev Med Public Health. 2012; 45: 219-226
        • Zint K.
        • Haefeli W.E.
        • Glynn R.J.
        • et al.
        Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults.
        Pharmacoepidemiol Drug Saf. 2010; 19: 1248-1255
        • Lai S.W.
        • Lin C.L.
        • Chen W.C.
        • Liao K.F.
        Correlation between use of zopiclone and risk of hip fracture in elderly adults: A case-control study in Taiwan.
        J Am Geriatr Soc. 2015; 63: 2534-2537
        • Foley D.J.
        • Monjan A.
        • Simonsick E.M.
        • et al.
        Incidence and remission of insomnia among elderly adults: An epidemiologic study of 6,800 persons over three years.
        Sleep. 1999; 22: S366-S372
        • Cunnington D.
        Non-benzodiazepine hypnotics: Do they work for insomnia?.
        BMJ. 2013; 346: e8699
        • Huedo-Medina T.B.
        • Kirsch I.
        • Middlemass J.
        • et al.
        Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration.
        BMJ. 2012; 345: e8343
        • Briesacher B.A.
        • Soumerai S.B.
        • Field T.S.
        • et al.
        Nursing home residents and enrollment in Medicare Part D.
        J Am Geriatr Soc. 2009; 57: 1902-1907
        • Centers for Medicare and Medicaid Services
        Long-Term Care Facility Resident Assessment Instrument 2.0 User's Manual.
        (Available at:) (Accessed May 27, 2015)
        • Mor V.
        A comprehensive clinical assessment tool to inform policy and practice: Applications of the minimum data set.
        Med Care. 2004; 42: III50-III59
        • Maclure M.
        The case-crossover design: A method for studying transient effects on the risk of acute events.
        Am J Epidemiol. 1991; 133: 144-153
        • Laine J.C.
        • Nguyen T.Q.
        • Buckley J.M.
        • Kim H.T.
        Effects of mixing techniques on vancomycin-impregnated polymethylmethacrylate.
        J Arthroplasty. 2011; 26: 1562-1566
        • Ray W.A.
        • Griffin M.R.
        • Fought R.L.
        • Adams M.L.
        Identification of fractures from computerized Medicare files.
        J Clin Epidemiol. 1992; 45: 703-714
        • Rigler S.K.
        • Ellerbeck E.
        • Whittle J.
        • et al.
        Comparing methods to identify hip fracture in a nursing home population using Medicare claims.
        Osteoporos Int. 2011; 22: 57-61
        • Ray W.A.
        Evaluating medication effects outside of clinical trials: New-user designs.
        Am J Epidemiol. 2003; 158: 915-920
        • Morris J.N.
        • Fries B.E.
        • Morris S.A.
        Scaling ADLs within the MDS.
        J Gerontol A Biol Sci Med Sci. 1999; 54: M546-M553
        • Field T.S.
        • Gurwitz J.H.
        • Avorn J.
        • et al.
        Risk factors for adverse drug events among nursing home residents.
        Arch Intern Med. 2001; 161: 1629-1634
        • American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society
        2015 updated Beers Criteria for potentially inappropriate medication use in older adults.
        J Am Geriatr Soc. 2015; 63: 2227-2246
        • Ray W.A.
        • Thapa P.B.
        • Gideon P.
        Misclassification of current benzodiazepine exposure by use of a single baseline measurement and its effects upon studies of injuries.
        Pharmacoepidemiol Drug Saf. 2002; 11: 663-669
        • de Souto Barreto P.
        • Lapeyre-Mestre M.
        • Cestac P.
        • et al.
        Effects of a geriatric intervention aiming to improve quality care in nursing homes on benzodiazepine use and discontinuation.
        Br J Clin Pharmacol. 2016; 81: 759-767
        • Hwang H.J.
        • Kim S.H.
        • Lee K.S.
        Potentially inappropriate medications in the elderly in Korean long-term care facilities.
        Drugs Real World Outcomes. 2015; 2: 355-361